目的 探讨血必净注射液与马来酸依那普利片、阿托伐他汀钙片联合对高血压肾损害患者临床疗效及肾功能的影响。方法 选取2014年12月—2017年12月榆林市第二医院100例高血压肾损害患者为研究对象，根据入院单双号将入选者分为对照组和观察组，每组50例。对照组患者口服马来酸依那普利片10 mg/次，1次/d；阿托伐他汀钙片10 mg/次，1次/d。观察组患者在对照组治疗的基础上静脉滴注血必净注射液，将1.5 g加入到0.9%氯化钠溶液100 mL中，1次/d。两组均连续治疗6个月。观察两组患者的临床疗效，比较两组治疗前后的肾功能指标、D-二聚体（D-D）和炎性因子水平。结果 治疗后，观察组总有效率为92.00%，显著高于对照组的76.00%，两组比较差异具有统计学意义（P<0.05）。治疗后，两组肌酐（Cr）、尿微量白蛋白与肌酐比值（ACR）、尿微量白蛋白（mAlb）及尿β₂-微球蛋白（β₂-MG）水平均显著降低（P<0.05）；且观察组肾功能指标水平显著低于对照组（P<0.05）。治疗后，两组患者的D-D、白细胞介素-6（IL-6）、超敏C反应蛋白（hs-CRP）和肿瘤坏死因子-α（TNF-α）水平均显著降低（P<0.05）；且观察组D-D及各炎性因子水平显著低于对照组（P<0.05）。结论 血必净注射液联合马来酸依那普利片和阿托伐他汀钙片治疗高血压肾损害患者可有效改善肾功能，抑制机体炎性反应，疗效安全显著，值得临床推广使用。

Objective To explore the effect of Xuebijing Injection combined with Enalapril Maleate Tablets and Atorvastatin Calcium Tablets on clinical efficacy and renal function in patients with hypertensive renal damage. Methods Patients (100 case) with hypertensive renal damage in Yulin Second Hospital from December 2014 to December 2017 were devided into control and observation groups according to the admission single and double number, and each group had 50 cases. Patients in the control group were po administered with Enalapril Maleate Tablets, 10 mg/time, once daily, and Atorvastatin Calcium Tablets, 10 mg/time, once daily. Patients in the observation group were iv administered with Xuebijing Injection on the basis of control group, 1.5 g added into 0.9% sodium chloride solution 100 mL, once daily. Patients in two groups were treated for 6 months. After treatment, the clinical efficacies were observed, and renal function indicators, D-D and serum factor levels in two groups before and after treatment were compared. Results After treatment, the total effective rate in the observation group was 92.00%, which was significantly higher than 76.00% in the control group, and there was difference between two groups (P<0.05). After treatment, the levels of Cr, ACR, mAlb and β₂-MG in two groups were significantly reduced (P<0.05), and the renal function indicators in the observation group were significantly lower than those in the control group (P<0.05). After treatment, the levels of D-D, IL-6, hs-CRP and TNF-α in two groups were significantly decreased (P<0.05), and the levels of D-D and inflammatory factors in the observation group were significantly lower than those in the control group (P<0.05). Conclusion Xuebijing Injection combined with Enalapril Maleate Tablets and Atorvastatin Calcium Tablets in treatment of patients with hypertensive renal damage can effectively improve the renal function, inhibit the body's inflammatory response, and significant safety, which was worthy of clinical application.